Document is current
Any future updates will be listed below
-
Authors
Li, Wei https://orcid.org/0000-0003-1186-8609
Yosipovitch, Gil https://orcid.org/0000-0001-6303-1822
-
Funding
Funding for this research was provided by:
Laboratoires Dermatologiques Avène–Pierre Fabre Dermo-Cosmétique
- License Information
-
More Information
Article History
First Online: 10 September 2020
Declarations
:
: Medical writing assistance was funded by Laboratoires Dermatologiques Avène–Pierre Fabre Dermo-Cosmétique.
: Gil Yosipovitch has acted as consultant and scientific advisory board member for Trevi, Pfizer, Galderma, Novartis, Sanofi Regeneron, Pierre Fabre, and LEO, and has had research sponsored by Pfizer, Sun Pharma, Novartis, LEO, and Sanofi Regeneron. Wei Li has received consultancy/speaker honoraria from Sanofi Regeneron, Pfizer, Lilly, Novartis, LEO, Pierre Fabre, MEDA Pharma (a Mylan Company), Astellas, and Galderma, and has participated as Principal Investigator in clinical trials sponsored by Sanofi Regeneron.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: This article is published as part of a journal supplement wholly funded by Laboratoires Dermatologiques Avène–Pierre Fabre Dermo-Cosmétique.
